Based on the findings that CD133 was explicitly expressed in small cell lung cancer (SCLC) but not in other types of lung cancer, such as adenocarcinoma and squamous cell carcinoma or adjacent healthy tissues, Kunihiro et al. proposed a strategy for early detection of SCLC that involved CD133 based PET imaging and autoantibody detection. This evidence concerns the gene PROM1 and lung carcinoma.